HeartFlow, a developer of non-invasive artificial intelligence (AI) precision coronary care solutions, has announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT—coronary computed tomography angiography (CCTA)-derived fractional flow reserve (FFR) —analysis.
Traditional methods of non-invasive ischaemia testing can result in false negatives 20–30% of the time, the company said in a press release which can lead to undetected disease, and false positives over 50% of the time, which can lead to unnecessary invasive procedures.
CCTA and HeartFlow’s FFRCT can non-invasively diagnose coronary artery disease and provides guidance on subsequent treatment decisions. HeartFlow’s FFRCT provides insights into each patient’s condition with a patient-specific visual model of the heart’s blood flow.
Last year marked the release of HeartFlow’s Plaque Analysis—a US Food and Drug Administration (FDA) cleared plaque analysis with a reported 95% agreement compared to the gold standard, intravascular ultrasound (IVUS), in quantification and characterisation of total plaque volume as shown in the REVEALPLAQUE study presented at 2023 Society of Cardiovascular Computed Tomography (SCCT) conference (27–30 July, Boston, USA).
Also in 2023, HeartFlow released its RoadMap analysis which helps identify and quantify narrowings in the coronary arteries.
“Accurate and timely diagnosis and treatment are fundamental to providing effective care, minimising risks, preventing complications and improving the overall health for patients with coronary artery disease,” said Daniel I Simon (University Hospitals Health System, Cleveland, USA). “Our long-standing partnership with HeartFlow has directly contributed to enhanced diagnostic precision, improved turnaround times, a reduction in false positives and negatives, and a better patient experience. Complementing our clinical expertise, HeartFlow’s portfolio allows us to navigate the complex cardiac diagnostic and treatment process with enhanced visibility, greater confidence and the assurance that we are maximising the potential for improved outcomes.”
“We are extremely proud of achieving the 250,000 patient milestone with our physician partners. Our collective team shares in our excitement for the future and are eager to build on this success.” said John Farquhar, chief executive officer at HeartFlow. “We’ve experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap analysis. Our continued commitment to developing a new standard of care for patients at risk of heart disease remains steadfast and we look forward to surpassing more milestones in the future.”
